# CANagliflozin In DIALysis Patients

> **NCT07527390** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 10 (estimated)

## Conditions studied

- Dialysis
- Chronic Kidney Disease (Stages 4 and 5)

## Interventions

- **DRUG:** Invokana 300 mg and 100 mg tablet

## Key facts

- **NCT ID:** NCT07527390
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527390, "CANagliflozin In DIALysis Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07527390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*